Primary and secondary outcomes of the randomized clinical trial groups at 3 months and 12 months. by Teemu P. Hevonkorpi (11577571)

Subjects:

Baseline characteristics of 291 patients by randomization group. by Teemu P. Hevonkorpi (11577571)

Subjects:

Adverse events at 12-month follow-up by study group. by Teemu P. Hevonkorpi (11577571)

Subjects:

Participant flow diagram of the DRIFT trial. by Teemu P. Hevonkorpi (11577571)

Subjects:

Between-group differences of mean PRWE with 95% confidence intervals in primarily malaligned DRFs and early malaligned DRFs at 3-month and 12-month follow-up. by Teemu P. Hevonkorpi (11577571)

Subjects:

S1 Graphical abstract - by Aman Goyal (19231397)

“…</p><p>Results</p><p>Between 1999 and 2020, 155,320 deaths were reported in patients with paroxysmal tachycardia. Overall, AAMR decreased from 4.8 to 3.7 per 100,000 population between 1999 and 2020, despite showing a significant increase from 2014 to 2020 (APC: 4.33; 95% CI: 3.53 to 5.56). …”

Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

Effects of S100A6 on CayBP/SIP-mediated β –catenin degradation. by Xiaoxuan Ning (334218)

“…<p>(A) Co-immunoprecipitation assay showed that truncated mutant CacyBP/SIPΔS100 bind both Skp1 and Siah1, suggesting S100A6 did not affect the formation of Siah1-CacyBP/SIP-Skp1 unbiquitin ligase complex. …”

Induced expression of miR-146a decreases NF-κB activation. by Sakthi Priya Selvamani (607420)

“…(<b>C</b>) Western blot analysis of p- NF-κB (p65) and total NF-κB (p65) protein expression levels in primary human synovial fibroblasts transfected with 100 pm scrambled and 100 pm miR-146a mimics. Increase in miR-146a significantly decreases p- NF-κB (p65) levels compared to controls and scramble miR-146a. …”

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Y86 is critical for SERINC3/5 antagonism by SIVcol Nef. by Dorota Kmiec (5646374)

Fig 5 - by Harshita Sharma (4836180)

Changes in the body color of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) across different feed treatment groups (Control, AX100, AX100 + BP, AX200, AX200 + BP) over time. by Wei-Wei Hou (3405947)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

H₂O₂-induced mitochondrial size decrease is prevented by WY pre-treatment in hippocampal neurons. by Juan M. Zolezzi (586604)

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Metformin inhibits glutaminase activity in a dose dependent manner: from 17.5% at 10 mM up to 68% at 100 mM (A) (* p<0.05). by M. Mar Díaz-Herrero (646639)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

Low doses of S100A14 stimulate cell proliferation and promote cell survival. by Qing'e Jin (222695)

“…(<b>I</b>) 10 µg/ml S100A14 decreased the percentage of sub-G1 phase of KYSE180 cells with the treatment of Dox (0.5 µM, 48 h). …”